Brief: Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus

Marinus Pharmaceuticals

17/06/2024 12:10

June 17 (Reuters) - Marinus Pharmaceuticals Inc
 MRNS.O :
    * MARINUS PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM
PHASE 3
RAISE TRIAL OF IV GANAXOLONE IN REFRACTORY STATUS EPILEPTICUS
    * MARINUS PHARMACEUTICALS INC: RAISE TRIAL MET ITS FIRST
CO-PRIMARY ENDPOINT
    * MARINUS PHARMACEUTICALS INC: FAILED TO ACHIEVE STATISTICAL
SIGNIFICANCE ON SECOND CO-PRIMARY ENDPOINT
    * MARINUS PHASE 3 RAISE TRIAL MET FIRST ENDPOINT
    * MARINUS EXPECTS PHASE 3 TRUSTTSC DATA IN Q4 2024
    * MARINUS PHARMACEUTICALS INC: PROJECTS CASH RUNWAY INTO Q2
2025

Source text for Eikon:  ID:nBw78vPmVa 
Further company coverage:  MRNS.O 

 ((Reuters.Briefs@thomsonreuters.com;))